Wheeler Bio

Examining the Future of Biomanufacturing through a Funding Lens

Our team gathered insights from C-Suite, portfolio managers, and market analysts from leading North American PE and VC firms focused on the biotech sector for Wheeler Bio. The survey provided a look into their investment strategies, preferences around target therapeutic areas, and expectations for valuation and exit based on size and phase when funding early-stage companies in the clinical phases of large molecule biologics development. The report was then used to generate leads for a biologics CDMO, specifically targeting emerging biotech clients.